4,070,681 no par value common shares in bearer form with an imputed nominal value of EUR1.00 by EUR56,360.00 to EUR4,127,041.00. Dr. Peter Heinrich, CEO of MagForce AG, along with interna- tional investors participated in the share placement. The company excluded subscription rights to existing shareholders by its authority. A total of 56,360.00 new common bearer shares with profit participation rights dating from January 1, 2011 were issued in the private placement at a price of EUR12.42 per
share. The gross proceeds of the capital increase in the amount of approx. EUR700,000.00 will go to the company and will be used to finance its further growth.
Moreover, the Company announced the treatment of a recurrent glioblastoma patient with the company‘s NanoTherm®
therapy. The first part of the therapy
(instillation of the nanoparticles) was carried out at the University Giessen and subsequent steps (nano-
11-09 :: September 2011